The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Autoimmune Gastrointestinal Dysmotility Market Grow Between 2026 And 2030?
The autoimmune gastrointestinal dysmotility market has experienced robust growth in recent years. It is forecast to grow from $1.82 billion in 2025 to $1.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The historical expansion of this market can be attributed to factors such as increased autoimmune disease diagnosis, the prevalence of gastroparesis, the expansion of hospital gastroenterology services, the usage of immunosuppressive drugs, and greater awareness of rare diseases.
The autoimmune gastrointestinal dysmotility market is anticipated to show considerable growth over the next few years, with its size projected to reach $2.63 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.2%. This growth throughout the forecast period is fueled by improvements in early diagnostics, personalized treatment approaches, the rising demand for long-term care, the increased use of home-based nutrition therapy, and the expansion of autoimmune research. Significant trends during this period are expected to include heightened recognition of rare gastrointestinal disorders, an increase in the utilization of immunosuppressive treatments, the broader implementation of nutritional and dietary management, the growing adoption of multidisciplinary care approaches, and an emphasis on long-term symptom management.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
Which Factors Are Influencing The Growth Of The Autoimmune Gastrointestinal Dysmotility Market?
The rise in clinical trials is projected to fuel the expansion of the autoimmune gastrointestinal dysmotility market in the future. These research investigations assess the safety, effectiveness, and best application of medical interventions, such as medications, biologics, devices, and treatment strategies, in human subjects to enhance medical understanding and patient care. The growing volume of clinical trials mainly stems from broadened regulatory guidelines necessitating trial registration, increased investment in pharmaceutical research and development, and the rapid progression of innovation in new therapeutic approaches like immunotherapies and biologics for autoimmune conditions impacting gastrointestinal motility. For autoimmune gastrointestinal dysmotility, clinical trials contribute to improving treatment options by systematically evaluating novel immunosuppressive therapies, prokinetic agents, and biologics, determining optimal treatment protocols for managing these motility disorders, and laying down evidence-based methods that facilitate regulatory approvals and the clinical adoption of pioneering therapies aimed at autoimmune-driven gastrointestinal dysfunction. For instance, in November 2025, according to ClinicalTrials.gov, a US-based clinical trials registry managed by the National Institutes of Health, the total number of registered clinical studies reached 477,203 at the end of 2023 (comprising 437,493 cumulative and 39,710 new registrations) and increased to 520,877 at the end of 2024 (comprising 477,203 cumulative and 43,674 new registrations), representing a 9.1% year-on-year increase in total registered studies. Consequently, the increasing number of clinical trials is stimulating growth within the autoimmune gastrointestinal dysmotility market.
What Segment Categories Shape The Autoimmune Gastrointestinal Dysmotility Market Segment Landscape?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented –
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs)
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
Who Are The Companies Operating Across The Autoimmune Gastrointestinal Dysmotility Market Value Chain?
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
Get The Full Autoimmune Gastrointestinal Dysmotility Market Report:
Where Is The Autoimmune Gastrointestinal Dysmotility Market Most Concentrated Geographically?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2025. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Autoimmune Gastrointestinal Dysmotility Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Autoimmune Gastrointestinal Dysmotility Market 2026, By The Business Research Company
Autoimmune Disease Diagnosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report
Autoimmune Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
Veterinary Autoimmune Disease Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model